肿瘤患者CD4^+CD25^+调节性T细胞流式细胞术分析

The profile of CD4^+ CD25^+T regulatory lymphocytes subpopulation in patients with cancer by flow cytometry

目的:分析比较肿瘤患者和健康人外周血CD4^+CD25^+调节性T细胞的特点,为肿瘤免疫学研究及治疗探索新方法。方法:收集并分离30例肿瘤患者和32例健康人的外周血单个核细胞(PBMCs),用荧光标记的抗人CD4及抗人CD25单抗标记肿瘤患者和健康人PBMCs细胞,FCM检测CD4^+CD25^+Treg细胞,分析CD4^+CD25^+Treg细胞在肿瘤患者和健康人中的差别。结果:肿瘤患者的CD4^+CD25^+Treg细胞百分数明显高于健康人(年龄<55者62.4 vs 40.4;年龄≥55者53.1 vs 31.0,P<0.05)。结论:肿瘤患者的CD4^+CD25^+Treg细胞高于健康对照,为肿瘤免疫治疗提供新策略,通过删除CD4^+CD25^+Treg细胞,有可能增强抗瘤免疫反应。

Objeclive：The alteration of CD4^＋ CD25^＋T regulatory lymphocytes （ CD4^＋ CD25^＋Treg cells） subpopulation in peripheral blood mononuclear cells （PBMCs） from patients with cancer was analyzed, and to explore a new strategy for tumor immunity and tumor immunotherapy. Methods： Peripheral blood mononuclear ceils （PBMCs） from 30 cases of various cancer patients and 32 healthy controls were collected. PBMCs of patients and health controls were stained by PE anti - human CD4 antibody and FITC anti - human CD25 antibody. The frequency of CD4^＋ CD25^＋Treg cells was identified by flow cytometry, and the CD4^＋ CD25^＋Treg cells of patients with cancer compared with healthy controls. Results： The results showed that the CD4^＋ CD25^＋Treg cells from patients with cancer were signifi- cantly higher than that of healthy controls （ aged 〈 55 62.4 vs 40.4 ; aged ~〉 55 53.1 vs 31.0, P 〈 0.05 ）. Conclusion： The CD4^＋ CD25^＋Treg cells from patients with cancer were higher than that of healthy controls, the results provide a new basis for the design of future tumor immunotherapeutic strategies. To neutralize CD4^＋ CD25^＋Treg in patients with cancer will enhance the efficacy of anticancer immunizations.